These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18841188)

  • 1. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.
    Kunac DL; Harrison-Woolrych M; Tatley MV
    N Z Med J; 2008 Oct; 121(1283):76-89. PubMed ID: 18841188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting adverse reactions to medicines.
    Ferguson R
    Nurs N Z; 1999 Dec-2000 Jan; 5(11):11. PubMed ID: 12008207
    [No Abstract]   [Full Text] [Related]  

  • 3. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre.
    Robson H; Braund R; Glass M; Ashton J; Tatley M
    Clin Toxicol (Phila); 2021 Jun; 59(6):472-479. PubMed ID: 33156704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypnosedative access and risk of harm.
    Menkes DB; Shieffelbien LM; Huthwaite M
    N Z Med J; 2011 Nov; 124(1345):69-73. PubMed ID: 22072169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants].
    Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML
    Therapie; 1997; 52(2):97-103. PubMed ID: 9231502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance of serious adverse drug reactions in New Zealand children.
    Kunac D; Tatley MV; Grimwood K; Reith DM
    Arch Dis Child; 2012 Aug; 97(8):761-2. PubMed ID: 22563042
    [No Abstract]   [Full Text] [Related]  

  • 8. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regional Centers of Pharmacovigilance: a complementary source of efficiency].
    Mazé F; Bégaud B
    Therapie; 1998; 53(4):397-400. PubMed ID: 9806011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Centre for Adverse Reactions Monitoring report for the period 1 July, 1994 to 3 June, 1996.
    Pillans P
    N Z Med J; 1997 Oct; 110(1053):383-5. PubMed ID: 9364188
    [No Abstract]   [Full Text] [Related]  

  • 13. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of data mining in pharmacovigilance.
    Hauben M; Madigan D; Gerrits CM; Walsh L; Van Puijenbroek EP
    Expert Opin Drug Saf; 2005 Sep; 4(5):929-48. PubMed ID: 16111454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The New Zealand Centre for Adverse Reactions Monitoring: a source of practice-based evidence.
    Savage R
    J Prim Health Care; 2013 Jun; 5(2):170-3. PubMed ID: 23748404
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS).
    Shin JY; Jung SY; Ahn SH; Lee SH; Kim SJ; Seong JM; Chung SY; Park BJ
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1115-22. PubMed ID: 25251052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Swiss Centre of Pharmacovigilance].
    Kuhn M; Hartmann K; Gartmann J
    Therapie; 1993; 48(5):465-7. PubMed ID: 8146826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.